Literature DB >> 9875906

Effects of hyperbaric oxygen exposure on a zymosan-induced shock model.

C Luongo1, F Imperatore, S Cuzzocrea, A Filippelli, M A Scafuro, G Mangoni, F Portolano, F Rossi.   

Abstract

OBJECTIVE: To evaluate the effects of hyperbaric oxygen (HBO) therapy on zymosan-induced shock in rats. Zymosan, a cell wall component of the yeast Saccharomyces cerevisiae, induces inflammation by causing the production of various cytokines and pro-inflammatory mediators. The administration of zymosan to rats represents a new experimental shock model by inducing acute peritonitis, severe hypotension, and signs of systemic illness. However, it has been recently proposed that the zymosan-induced shock, like septic shock, may be mediated by overproduction of nitric oxide.
DESIGN: Experimental study.
SETTING: Institute of Pharmacology and Toxicology, 2nd University of Naples, Naples, Italy.
SUBJECTS: Male rats were treated with zymosan (500 mg/kg) by intraperitoneal route, with HBO (2 Absolute Atmosphere) or with zymosan and HBO (2 Absolute Atmosphere).
MEASUREMENTS AND MAIN RESULTS: Peritoneal exudate, plasma, and peritoneal nitric oxide metabolites (NOx) and zymosan determined a time-dependent increase in peritoneal and plasma NOx concentrations, and peritoneal leukocytes were determined. Moreover, symptomatology was observed. The administration of zymosan caused the appearance of a severe illness in the rats characterized by ruffled fur, lethargy, conjunctivitis, diarrhea, and a significant loss of body weight. All zymosan-treated rats developed an acute peritonitis, producing turbid exudate. Zymosan determined a time-dependent increase in peritoneal, plasma NOx, and tumor necrosis factor (TNF)-alpha concentrations. Morbidity of zymosan shocked rats has been attenuated and no mortality was observed by treatment with HBO. These findings were associated with a significant reduction either of peritoneal leukocytes and exudate, or plasma and peritoneal NOx concentrations. Moreover, TNF-alpha levels were significantly reduced in animals shocked by zymosan and treated with HBO.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9875906     DOI: 10.1097/00003246-199812000-00022

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  21 in total

1.  Hyperbaric oxygen in systemic inflammatory response.

Authors:  Haim Bitterman; Claus-Martin Muth
Journal:  Intensive Care Med       Date:  2004-03-18       Impact factor: 17.440

2.  Hyperbaric oxygen therapy prevents coagulation disorders in an experimental model of multiple organ failure syndrome.

Authors:  Francesco Imperatore; Salvatore Cuzzocrea; Domenico De Lucia; Marcella Sessa; Barbara Rinaldi; Annalisa Capuano; Giovanni Liguori; Amelia Filippelli; Francesco Rossi
Journal:  Intensive Care Med       Date:  2006-09-15       Impact factor: 17.440

3.  Hyperbaric oxygen and sepsis: time to recognize.

Authors:  Claus-Martin Muth; Peter Radermacher; Salvatore Cuzzocrea
Journal:  Intensive Care Med       Date:  2005-07-21       Impact factor: 17.440

4.  Can (hyperbaric) oxygen turn off the motor of multiorgan dysfunction?

Authors:  Sükrü Oter; Peter Radermacher; Martin Matejovic
Journal:  Intensive Care Med       Date:  2006-09-30       Impact factor: 17.440

5.  Effects of hyperoxia exposure on metabolic markers and gene expression in 3T3-L1 adipocytes.

Authors:  P Quintero; P González-Muniesa; D F García-Díaz; J A Martínez
Journal:  J Physiol Biochem       Date:  2012-04-26       Impact factor: 4.158

6.  Hyperbaric oxygen therapy reduces the toll-like receptor signaling pathway in multiple organ failures.

Authors:  Barbara Rinaldi; Salvatore Cuzzocrea; Maria Donniacuo; Annalisa Capuano; Donatella Di Palma; Francesco Imperatore; Emanuela Mazzon; Rosanna Di Paola; Loredana Sodano; Francesco Rossi
Journal:  Intensive Care Med       Date:  2011-05-13       Impact factor: 17.440

7.  Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages.

Authors:  R M Benson; L M Minter; B A Osborne; E V Granowitz
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

8.  Hyperbaric oxygen treatment attenuates the pro-inflammatory and immune responses in apolipoprotein E knockout mice.

Authors:  Bhalchandra Kudchodkar; Harlan Jones; Jerry Simecka; Ladislav Dory
Journal:  Clin Immunol       Date:  2008-07-02       Impact factor: 3.969

9.  Effects of hyperbaric oxygen on intestinal mucosa apoptosis caused by ischemia-reperfusion injury in rats.

Authors:  Shi-Hui Zhou; Yan-Fei Sun; Gang Wang
Journal:  World J Emerg Med       Date:  2012

Review 10.  Bench-to-bedside review: oxygen as a drug.

Authors:  Haim Bitterman
Journal:  Crit Care       Date:  2009-02-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.